Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Ceramide analog SACLAC modulates sphingolipid levels and Mcl-1 splicing to induce apoptosis in acute myeloid leukemia.

Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, Fabrias G, Desai D, Amin S, Wang HG, Cabot MC, Claxton DF, Kester M, Feith DJ, Loughran TP.

Mol Cancer Res. 2019 Nov 19. pii: molcanres.0619.2019. doi: 10.1158/1541-7786.MCR-19-0619. [Epub ahead of print]

PMID:
31744877
2.

Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Kao LP, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, Fox TE, Kester M, Loughran TP Jr, Abad JL, Fabrias G, Tan SF, Feith DJ, Claxton DF, Spiegel S, Fisher-Wellman KH, Cabot MC.

J Lipid Res. 2019 Sep;60(9):1590-1602. doi: 10.1194/jlr.RA119000251. Epub 2019 Jul 30.

PMID:
31363040
3.

Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.

Morad SAF, MacDougall MR, Abdelmageed N, Kao LP, Feith DJ, Tan SF, Kester M, Loughran TP Jr, Wang HG, Cabot MC.

Exp Cell Res. 2019 Aug 15;381(2):256-264. doi: 10.1016/j.yexcr.2019.05.021. Epub 2019 May 18.

PMID:
31112736
4.

Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Tan SF, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, Doi K, Conaway MR, Amin S, Claxton DF, Wang HG, Kester M, Cabot MC, Feith DJ, Loughran TP Jr.

J Lipid Res. 2019 Jun;60(6):1078-1086. doi: 10.1194/jlr.M091876. Epub 2019 Apr 8.

PMID:
30962310
5.

The Onus of Sphingolipid Enzymes in Cancer Drug Resistance.

Morad SAF, Cabot MC.

Adv Cancer Res. 2018;140:235-263. doi: 10.1016/bs.acr.2018.04.013. Epub 2018 Jun 5. Review.

PMID:
30060811
6.

Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Morad SAF, Davis TS, MacDougall MR, Tan SF, Feith DJ, Desai DH, Amin SG, Kester M, Loughran TP Jr, Cabot MC.

Biochem Pharmacol. 2017 Apr 15;130:21-33. doi: 10.1016/j.bcp.2017.02.002. Epub 2017 Feb 9.

7.

Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

8.

Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP Jr, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC.

J Lipid Res. 2016 Jul;57(7):1231-42. doi: 10.1194/jlr.M067389. Epub 2016 May 2.

9.

Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells.

Morad SA, Bridges LC, Almeida Larrea AD, Mayen AL, MacDougall MR, Davis TS, Kester M, Cabot MC.

Cancer Lett. 2016 Jul 1;376(2):199-204. doi: 10.1016/j.canlet.2016.03.049. Epub 2016 Apr 1.

PMID:
27045476
10.

Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.

Morad SA, Davis TS, Kester M, Loughran TP Jr, Cabot MC.

Leuk Res. 2015 Oct;39(10):1071-8. doi: 10.1016/j.leukres.2015.06.009. Epub 2015 Jul 2.

11.

Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Morad SA, Cabot MC.

Biochim Biophys Acta. 2015 Sep;1851(9):1134-45. doi: 10.1016/j.bbalip.2015.05.001. Epub 2015 May 9. Review.

12.

Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP Jr, Barth BM, Fox TE, Cabot MC.

Biochim Biophys Acta. 2015 Jul;1851(7):919-28. doi: 10.1016/j.bbalip.2015.03.001. Epub 2015 Mar 10.

13.

Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.

Barth BM, Keasey NR, Wang X, Shanmugavelandy SS, Rampal R, Hricik T, Cabot MC, Kester M, Wang HG, Shultz LD, Tallman MS, Levine RL, Loughran TP Jr, Claxton DF.

J Leuk (Los Angel). 2014 Sep;2(3). pii: 146. doi: 10.4172/2329-6917.1000146. Epub 2014 Jul 25.

14.

Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.

Morad SA, Levin JC, Tan SF, Fox TE, Feith DJ, Cabot MC.

Biochim Biophys Acta. 2013 Dec;1831(12):1657-64. doi: 10.1016/j.bbalip.2013.07.016. Epub 2013 Aug 9.

PMID:
23939396
15.

Gaucher's disease and cancer: a sphingolipid perspective.

Barth BM, Shanmugavelandy SS, Tacelosky DM, Kester M, Morad SA, Cabot MC.

Crit Rev Oncog. 2013;18(3):221-34. Review.

16.

Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.

Morad SA, Madigan JP, Levin JC, Abdelmageed N, Karimi R, Rosenberg DW, Kester M, Shanmugavelandy SS, Cabot MC.

Biochem Pharmacol. 2013 Apr 15;85(8):1057-65. doi: 10.1016/j.bcp.2013.01.015. Epub 2013 Jan 24.

17.

Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells.

Morad SA, Messner MC, Levin JC, Abdelmageed N, Park H, Merrill AH Jr, Cabot MC.

Cancer Chemother Pharmacol. 2013 Mar;71(3):635-45. doi: 10.1007/s00280-012-2050-4. Epub 2012 Dec 21.

PMID:
23263160
18.

Ceramide-orchestrated signalling in cancer cells.

Morad SA, Cabot MC.

Nat Rev Cancer. 2013 Jan;13(1):51-65. doi: 10.1038/nrc3398. Epub 2012 Dec 13. Review.

PMID:
23235911
19.

Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.

Watters RJ, Fox TE, Tan SF, Shanmugavelandy S, Choby JE, Broeg K, Liao J, Kester M, Cabot MC, Loughran TP, Liu X.

Leuk Lymphoma. 2013 Jun;54(6):1288-96. doi: 10.3109/10428194.2012.752485. Epub 2012 Dec 31.

20.

Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.

Morad SA, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C, Cabot MC.

Mol Cancer Ther. 2012 Nov;11(11):2352-61. doi: 10.1158/1535-7163.MCT-12-0594. Epub 2012 Sep 7.

21.

C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.

Flowers M, Fabriás G, Delgado A, Casas J, Abad JL, Cabot MC.

Breast Cancer Res Treat. 2012 Jun;133(2):447-58. doi: 10.1007/s10549-011-1768-8. Epub 2011 Sep 21.

PMID:
21935601
22.

Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.

Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M.

Cancer Biol Ther. 2011 Oct 1;12(7):574-85. Epub 2011 Oct 1.

23.

Sphingolipid metabolism and drug resistance in hematological malignancies.

Gouaze-Andersson V, Cabot MC.

Anticancer Agents Med Chem. 2011 Nov;11(9):891-903. Review.

PMID:
21707483
24.

Ceramide-based therapeutics for the treatment of cancer.

Barth BM, Cabot MC, Kester M.

Anticancer Agents Med Chem. 2011 Nov;11(9):911-9. Review.

PMID:
21707481
25.

Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma.

Liu YY, Patwardhan GA, Xie P, Gu X, Giuliano AE, Cabot MC.

Int J Oncol. 2011 Aug;39(2):425-31. doi: 10.3892/ijo.2011.1052. Epub 2011 May 23.

26.

Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide.

Gouazé-Andersson V, Flowers M, Karimi R, Fabriás G, Delgado A, Casas J, Cabot MC.

Prostate. 2011 Jul;71(10):1064-73. doi: 10.1002/pros.21321. Epub 2010 Dec 28.

PMID:
21557271
27.

P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.

Chapman JV, Gouazé-Andersson V, Karimi R, Messner MC, Cabot MC.

Exp Cell Res. 2011 Jul 15;317(12):1736-45. doi: 10.1016/j.yexcr.2011.03.004. Epub 2011 Mar 21.

28.

Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells.

Messner MC, Cabot MC.

Cancer Chemother Pharmacol. 2011 Aug;68(2):477-87. doi: 10.1007/s00280-010-1504-9. Epub 2010 Nov 12.

PMID:
21072519
29.

Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity.

Chapman JV, Gouazé-Andersson V, Cabot MC.

Int J Oncol. 2010 Dec;37(6):1591-7.

PMID:
21042729
30.

Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance.

Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, Cabot MC, Kester M, Kuhn TB.

Cancer Biol Ther. 2010 Dec 1;10(11):1126-36. doi: 10.4161/cbt.10.11.13438. Epub 2010 Dec 1.

31.

Glucosylceramide in humans.

Messner MC, Cabot MC.

Adv Exp Med Biol. 2010;688:156-64. Review.

PMID:
20919653
32.

Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, Mehendale H, Cabot MC, Li YT, Jazwinski SM.

Mol Cancer. 2010 Jun 11;9:145. doi: 10.1186/1476-4598-9-145.

33.

Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.

Chapman JV, Gouazé-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE, Cabot MC.

Biochem Pharmacol. 2010 Aug 1;80(3):308-15. doi: 10.1016/j.bcp.2010.04.001. Epub 2010 Apr 10.

34.

Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase.

Gupta V, Patwardhan GA, Zhang QJ, Cabot MC, Jazwinski SM, Liu YY.

J Lipid Res. 2010 Apr;51(4):866-74. doi: 10.1194/jlr.D002949. Epub 2009 Oct 13.

35.

A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Patwardhan GA, Zhang QJ, Yin D, Gupta V, Bao J, Senkal CE, Ogretmen B, Cabot MC, Shah GV, Sylvester PW, Jazwinski SM, Liu YY.

PLoS One. 2009 Sep 9;4(9):e6938. doi: 10.1371/journal.pone.0006938.

36.

N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing.

Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, Symolon H, Liu Y, Merrill AH Jr, Gouazé-Andersson V, Yu JY, Giuliano AE, Cabot MC.

Mol Cancer Ther. 2008 Sep;7(9):2967-76. doi: 10.1158/1535-7163.MCT-08-0549.

37.

A role for ceramide in driving cancer cell resistance to doxorubicin.

Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, Consoli DP, Cabot MC.

FASEB J. 2008 Jul;22(7):2541-51. doi: 10.1096/fj.07-092981. Epub 2008 Feb 1.

PMID:
18245173
38.

Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Gouazé-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC.

Biochim Biophys Acta. 2007 Dec;1771(12):1407-17. Epub 2007 Nov 9.

39.

Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison.

Arthur CR, Gupton JT, Kellogg GE, Yeudall WA, Cabot MC, Newsham IF, Gewirtz DA.

Biochem Pharmacol. 2007 Oct 1;74(7):981-91. Epub 2007 Jul 7.

40.

Glycosphingolipids and drug resistance.

Gouaze-Andersson V, Cabot MC.

Biochim Biophys Acta. 2006 Dec;1758(12):2096-103. Epub 2006 Aug 26. Review.

41.
42.

Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.

Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC.

Mol Cancer Ther. 2004 May;3(5):633-9.

43.

Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.

Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, Cabot MC.

J Lipid Res. 2004 May;45(5):933-40. Epub 2004 Feb 16.

44.

Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.

Kalli KR, Devine KE, Cabot MC, Arnt CR, Heldebrant MP, Svingen PA, Erlichman C, Hartmann LC, Conover CA, Kaufmann SH.

Mol Pharmacol. 2003 Dec;64(6):1434-43.

PMID:
14645674
45.

Development of a mammalian Tet-on expression cell line: glucosylceramide synthase regulates TNF-alpha-induced apoptosis.

Liu YY, Cabot MC.

Methods Mol Biol. 2004;249:177-92. No abstract available.

PMID:
14573900
46.

Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells.

Wang H, Charles AG, Frankel AJ, Cabot MC.

Urology. 2003 May;61(5):1047-52.

PMID:
12736045
47.

Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.

Litvak DA, Bilchik AJ, Cabot MC.

J Gastrointest Surg. 2003 Jan;7(1):140-148. doi: 10.1016/S1091-255X(02)00126-9.

PMID:
12559195
48.

Glucosylceramide synthase and apoptosis.

Bleicher RJ, Cabot MC.

Biochim Biophys Acta. 2002 Dec 30;1585(2-3):172-8. Review.

PMID:
12531551
50.

Sentinel lymphadenectomy: a new alternative for managing early breast cancer.

Bitterman A, Bleicher RJ, Cabot MC, Liu YY, Giuliano AE.

Isr Med Assoc J. 2002 Oct;4(10):803-9. Review. No abstract available.

Supplemental Content

Loading ...
Support Center